All In Biotech

Drug Trial Radar · NCT06427291

Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients

A Phase I, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Evaluate the Safety and Efficacy of T3011 in Patients With BCG-Failure Non-Muscle-Invasive Bladder Cancer (NMIBC)

Last checked: Nov 19, 2026Latest source record: May 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

20

Planned (sponsor's estimate)

Start

Sep 21, 2023

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label, single-arm investigator-initiated clinical study. It is used to evaluate the safety and efficacy of T3011 intravesical instillation in patients with BCG-failure high-risk non-muscle invasive bladder cancer (NMIBC)

Conditions

  • Bladder Cancer

Interventions

  • Herpes virus T3011 injectionBiological

    T3011 will be instilled in the entire solution volume of 50ml, and be will be left in the bladder for at least 1 hour, no more than 2 hours. After competing instillation, the patients should be instructed to drink at lest 1000mL of water

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CR rate or relapse-free survival rates at 3, 6, 9 and 12 months after the first study doseTime frame: 3, 6, 9 and 12 months after first study dose
  2. Recurrence-free survival, RFSTime frame: Up to 2 years
  3. Progression-free survival, PFSTime frame: Up to 2 years
  4. Incidence of radical cystectomyTime frame: Up to 2 years
  5. 5-year survival rateTime frame: Up to 5 years
  6. Adverse Events, AETime frame: up to 30 days after completion of treatment
  7. Serious Adverse Event, SAETime frame: up to 30 days after completion of treatment
  8. Dose-limiting toxicity (DLT) eventsTime frame: First cycle of treatment, i.e. within 28 days of first instillation
  9. Abnormal clinically significant vital signs and their incidenceTime frame: Up to 1 years
  10. Abnormal clinically significant physical findings and their incidenceTime frame: Up to 1 years
  11. Abnormal clinically significant laboratory findings and their incidenceTime frame: Up to 1 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.